Cytodifferentiation and clinical outcome after chemotherapy and radiation therapy for rhabdomyosarcoma (RMS)

Medical and Pediatric Oncology

Volumn 38, Issue 6, 2002, Pages 398-404

  Smith, Lynn M ^a,c   Anderson, James R ^b   Coffin, Cheryl M ^c  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

Author keywords

Cytodifferentiation; Proliferative activity; Rhabdomyosarcoma; Therapy induced changes

Indexed keywords

CD45 ANTIGEN; CHLORDANE; DNA TOPOISOMERASE (ATP HYDROLYSING); KI 67 ANTIGEN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PROTEIN P53;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CHILD; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; RHABDOMYOSARCOMA;

ADOLESCENT; ANTIGENS, NEOPLASM; ANTIGENS, NUCLEAR; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; KI-67 ANTIGEN; MALE; NUCLEAR PROTEINS; PROGNOSIS; RHABDOMYOSARCOMA; RHABDOMYOSARCOMA, ALVEOLAR; RHABDOMYOSARCOMA, EMBRYONAL; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036251964     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/mpo.10060     Document Type: Article

References (22)

1. The third Intergroup Rhabdomyosarcoma Study
2. Biology and therapy of pediatric rhabdomyosarcoma
3. Pathologic features of rhabdomyosarcoma before and after treatment: A clinicopathologic immunohistochemical analysis
4. Preservation of the bladder in patients with rhabdomyosarcoma
5. Presence of well-differentiated rhabdomyoblasts at the end of therapy for pelvic rhabdomyosarcoma: Implications for the outcome
6. Classification of rhabdomyosarcomas and related sarcomas pathological aspects and proposal for a unified classification. An Intergroup Rhabdomyosarcoma Study
7. Therapy associated differentiation in rhabdomyosarcomas
8. Cytologic differentiation in childhood rhabdomyosarcomas following polychemotherapy
9. Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung
10. Alpha 2 a-interferon-induced differentiation of human alveolar rhabdomyosarcoma cells: Correlation with down-regulation of the insulin-like growth factor type I receptor
11. Myogenic differentiation of human rhabdomyosarcoma cells induced in vitro by antineoplastic drugs
12. Actinomyocin D treatment leads to differentiation and inhibits proliferation in rhabdomyosarcoma cells
13. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma
14. Mechanisms of p53 loss in human sarcomas
15. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma
16. Therapy associated changes in childhood tumors
17. Skeletal muscle regeneration mimicking rhabdomyosarcoma: A potential diagnostic pitfall
18. Radiation and the lung: A re-evaluation of the mechanisms mediating pulmonary injury
19. Prognostic factors in patients with localized Ewing's sarcoma: The effect on survival of actual received drug dose intensity and of histologic response to induction therapy
20. Pre-operative chemotherapy for osteogenic sarcoma: Selection of post-operative adjuvant chemotherapy based on the response of the primary tumor to pre-operative chemotherapy
21. Neoadjuvant chemotherapy of osteosarcoma: Results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histologic tumor response
22. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing's sarcoma